<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00521079</url>
  </required_header>
  <id_info>
    <org_study_id>D00343-000</org_study_id>
    <nct_id>NCT00521079</nct_id>
  </id_info>
  <brief_title>EMPOWER Clinical Trial: Vagal Blocking for Obesity Control</brief_title>
  <acronym>EMPOWER</acronym>
  <official_title>EMPOWER Clinical Trial: Vagal Blocking for Obesity Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EnteroMedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EnteroMedics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized multi-center study being done to measure the ability of a new medical
      device, Maestro System, to safely reduce body weight over five years in people who are
      considered obese.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Maestro System is a neuromodulation system that consists of implantable and external
      components.

      Implantable components: two leads (one electrode each for the anterior and posterior
      intra-abdominal vagal nerve trunks) that are connected to an implantable neuroregulator.

      External components: one programmable, battery-powered, ambulatory external controller
      connected via a small, flexible cable to a cutaneous transmit coil that is positioned
      externally over the neuroregulator. A clinician programmer that transmits information to the
      controller and uploads data from the controller.

      All non-diabetic subjects will be randomized in a 2:1 allocation to therapy ON or therapy OFF
      groups. All type 2 diabetes mellitus subjects will be randomized in a 1:1 allocation to
      therapy ON or therapy OFF groups.

      All subjects will receive blinded therapy through the 12-month follow-up visit. All subjects
      will participate in a medical weight management program.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Excess Weight Loss (EWL) With the Maestro System</measure>
    <time_frame>Baseline and 1 Year</time_frame>
    <description>Observe at least a 10% greater percentage excess weight loss (%EWL) with vBloc therapy delivered by the Maestro System compared to sham 12 months following randomization using MetLife Method (ideal body weight is calculated based on Metropolitan Height and Weight Tables)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of System and Procedure-related Serious Adverse Events (SAEs).</measure>
    <time_frame>1 Year</time_frame>
    <description>To estimate the rate of serious, system- and procedure-related adverse events associated with the Maestro System.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving 25% Excess Weight Loss (%EWL)</measure>
    <time_frame>Baseline and 1 Year</time_frame>
    <description>To evaluate the percentage of participants achieving 25% excess weight loss from baseline (implant) to 12 months between treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">294</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>vBloc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects implanted with a functional Maestro System device that delivers therapy (Therapy ON).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects implanted with a functional Maestro System device that does NOT deliver therapy (Therapy OFF).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Therapy ON</intervention_name>
    <description>Intermittent, programmable, intra-abdominal vagal blocking device that delivers therapy (Therapy ON)</description>
    <arm_group_label>vBloc</arm_group_label>
    <other_name>Maestro System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Therapy OFF</intervention_name>
    <description>Active intra-abdominal placebo device that delivers no therapy (Therapy OFF)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Maestro System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Informed consent.

          2. Body mass index (BMI) ≥ 40 kg/m2 to 45 kg/m2 or BMI ≥ 35 kg/m2 to 39.9 kg/m2 with one
             or more obesity related co-morbid condition. Co-morbid conditions may include one or
             more of the following:

               -  Type 2 diabetes mellitus (note: type 2 diabetics are allowed at selected centers
                  only, see Inclusion criterion #5)

               -  Hypertension as defined by systolic pressure ≥140 mmHg and/or diastolic pressure
                  ≥90 mmHg a) treated or untreated with systolic ≥140 mmHg or diastolic ≥90 mmHg or
                  b) treated with systolic &lt;140 mmHg and diastolic &lt;90 mmHg

               -  Dyslipidemia as defined by total cholesterol ≥200 or LDL ≥130 a) treated or
                  untreated with total cholesterol ≥200 or LDL ≥130 or b) treated with total
                  cholesterol &lt;200 or LDL &lt;130

               -  Sleep apnea syndrome (confirmed by overnight p02 studies)

               -  Obesity related cardiomyopathy

          3. Females or males Note: females of child-bearing potential must have a negative urine
             pregnancy test at Screen and also within 14 days of implant procedure followed by
             physician-approved contraceptive regimen for the duration of the study period.

          4. 18-65 years of age inclusive.

          5. Type 2 diabetes mellitus subjects (at selected centers, limited to approximately 34
             subjects) with:

               -  Glycosylated hemoglobin (Hb A1c) 6.5 - 9 % inclusive at screening visit.

               -  Onset: 10 years or less since initial diagnosis.

               -  Stable treatment regimen: no change in oral hypoglycemic treatment regimen within
                  past 3 months.

               -  Currently not using insulin therapy, GLP-1 receptor agonists (e.g., exenatide),
                  or DPP-4 inhibitors (e.g., sitagliptin) for diabetes treatment and have not been
                  on these treatments in the past 6 months.

               -  Creatinine within normal reference range.

               -  No history of proliferative retinopathy.

               -  No history of peripheral neuropathy.

               -  No history of autonomic neuropathy.

               -  No history of coronary artery disease, with or without angina pectoris.

               -  No history of peripheral vascular disease.

          6. Failure to respond to supervised diet/exercise program(s) in which the subject was
             engaged for at least 6 months within the last five years.

          7. Ability to complete all study visits and procedures.

        Exclusion criteria

          1. Concurrent chronic pancreatic disease.

          2. History of Crohn's disease and/or ulcerative colitis.

          3. History of bariatric surgery, fundoplication, gastric resection or major
             upper-abdominal surgery (acceptable surgeries include cholecystectomy, hysterectomy).

          4. History of pulmonary embolism or blood coagulation disorders.

          5. Clinically significant hiatal hernias known from subject's medical record as or
             determined by upper endoscopy prior to implant if they have not had one done during
             the previous 6 months that specifically reported on the presence or absence of hiatal
             hernia making reference to the Z-line and/or diaphragmatic notch, in order to rule out
             subjects with hiatal hernia that may require surgical repair (to support exclusion
             criterion #7).

          6. Current portal hypertension and/or esophageal varices.

          7. Intra-operative exclusion: hiatal hernia requiring surgical repair or extensive
             dissection at esophagogastric junction at time of surgery.

          8. Treatment with weight-loss prescription drug therapy within the prior three months and
             the use of prescription drug therapy or the use over-the-counter weight loss
             preparations for the duration of the trial.

          9. Smoking cessation within the prior six months.

         10. Known genetic cause of obesity (e.g., Prader-Willi Syndrome).

         11. Overall sustained reduction of more than 10% of body weight in the previous 12 months.

         12. Physician-prescribed pre-operative diet with intent to lose weight prior to surgery
             (note: a) study subject may continue any personal diet they were on prior to study
             enrollment [see exclusion criterion #24] b) standardized EMPOWER weight management
             program to be initiated in all subjects at time of activation, approximately two weeks
             after implant)

         13. Current type 1 diabetes mellitus (DM).

         14. Current or recent history (within 12 months) of ongoing bulimia.

         15. Current alterations in treatment for thyroid disorders (stable treatment regimen for
             prior three months acceptable).

         16. Current alterations in treatment for epilepsy (stable treatment regimen for prior six
             months acceptable).

         17. Current treatment for peptic ulcer disease (previous history acceptable).

         18. Chronic (more than 4 weeks of daily use) treatment with narcotic analgesic drug
             regimens (treatment with non-steroidal anti-inflammatory drugs acceptable).

         19. Current alterations in treatment regimens of anti-cholinergic drugs, including
             tricyclic antidepressants (stable treatment regimen for prior six months acceptable).

         20. Current medical condition that, in the opinion of the investigator, would make subject
             unfit for surgery under general anesthesia or that would be exacerbated by intentional
             weight loss. Some examples include diagnosis of cancer, recent heart attack, recent
             stroke or recent serious trauma.

         21. Presence of permanently implanted electrical powered medical device or implanted
             gastrointestinal device or prosthesis (e.g., pacemakers, implanted defibrillators,
             neurostimulators etc.).

         22. Planned or contemplated use of Magnetic Resonance Imaging (MRI) or oncological
             radiation during the course of the trial.

         23. Significant psychiatric disorders that, in the opinion of the investigator, may
             interfere with subject's ability to follow study procedures and/or instructions.

         24. Current, active member of an organized weight loss program (e.g., Weight Watchers,
             TOPS).

         25. Current participant in another weight loss study or other clinical trials.

         26. Have a friend or family member who is currently participating or is planning to
             participate in this clinical trial.

         27. Patient reported:

               -  inability to walk for about 10 minutes without stopping,

               -  feeling of pain in chest when doing physical activity,

               -  feeling of pain in chest when not doing physical activity. Note: unless pain in
                  chest in known to be related to upper gastrointestinal disorders such as
                  gastroesophageal reflux disease or heartburn.

         28. Clinically significant cardiac rhythm disorder that requires either medical and/or
             surgical intervention (e.g., paroxysmal or chronic atrial fibrillation).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles J Billington, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Minneapolis, MN / University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Sarr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HonorHealth (formerly Scottsdale Bariatric Center)</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic - Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic - Ohio</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Weight Control</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2153</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adelaide Bariatric Center - Flinders Private Hospital</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2007</study_first_submitted>
  <study_first_submitted_qc>August 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2007</study_first_posted>
  <results_first_submitted>August 23, 2016</results_first_submitted>
  <results_first_submitted_qc>December 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 20, 2017</results_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Bariatric surgery</keyword>
  <keyword>Excess weight loss</keyword>
  <keyword>Vagus nerve</keyword>
  <keyword>Vagal blocking</keyword>
  <keyword>vBloc(TM) therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>vBloc</title>
          <description>Subjects implanted with a functional Maestro System device that delivers therapy (Therapy ON).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects implanted with a functional Maestro System device that does NOT deliver therapy (Therapy OFF).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Surgical Roll-In</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>vBloc</title>
          <description>Subjects implanted with a functional Maestro System device that delivers therapy (Therapy ON).</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects implanted with a functional Maestro System device that does NOT deliver therapy (Therapy OFF).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="183"/>
            <count group_id="B2" value="97"/>
            <count group_id="B3" value="280"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="280"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.7" spread="9.7"/>
                    <measurement group_id="B2" value="45.6" spread="10.6"/>
                    <measurement group_id="B3" value="45.7" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="248"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Excess Weight Loss (EWL) With the Maestro System</title>
        <description>Observe at least a 10% greater percentage excess weight loss (%EWL) with vBloc therapy delivered by the Maestro System compared to sham 12 months following randomization using MetLife Method (ideal body weight is calculated based on Metropolitan Height and Weight Tables)</description>
        <time_frame>Baseline and 1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>vBloc</title>
            <description>Subjects implanted with a functional Maestro System device that delivers therapy (Therapy ON).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects implanted with a functional Maestro System device that does NOT deliver therapy (Therapy OFF).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Excess Weight Loss (EWL) With the Maestro System</title>
          <description>Observe at least a 10% greater percentage excess weight loss (%EWL) with vBloc therapy delivered by the Maestro System compared to sham 12 months following randomization using MetLife Method (ideal body weight is calculated based on Metropolitan Height and Weight Tables)</description>
          <units>Percentage of excess weight loss</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" spread="2"/>
                    <measurement group_id="O2" value="16" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of System and Procedure-related Serious Adverse Events (SAEs).</title>
        <description>To estimate the rate of serious, system- and procedure-related adverse events associated with the Maestro System.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>vBloc</title>
            <description>Subjects implanted with a functional Maestro System device that delivers therapy (Therapy ON).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects implanted with a functional Maestro System device that does NOT deliver therapy (Therapy OFF).</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of System and Procedure-related Serious Adverse Events (SAEs).</title>
          <description>To estimate the rate of serious, system- and procedure-related adverse events associated with the Maestro System.</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving 25% Excess Weight Loss (%EWL)</title>
        <description>To evaluate the percentage of participants achieving 25% excess weight loss from baseline (implant) to 12 months between treatment groups.</description>
        <time_frame>Baseline and 1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>vBloc</title>
            <description>Subjects implanted with a functional Maestro System device that delivers therapy (Therapy ON).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects implanted with a functional Maestro System device that does NOT deliver therapy (Therapy OFF).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving 25% Excess Weight Loss (%EWL)</title>
          <description>To evaluate the percentage of participants achieving 25% excess weight loss from baseline (implant) to 12 months between treatment groups.</description>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Includes roll-in subjects.</desc>
      <group_list>
        <group group_id="E1">
          <title>vBloc</title>
          <description>Subjects implanted with a functional Maestro System device that delivers therapy (Therapy ON).</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects implanted with a functional Maestro System device that does NOT delivers therapy (Therapy OFF).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac abnormality</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain abdominal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Large bowel dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cold/flu/respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="192"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Reaction to medicines</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection neuroregulator site</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Infection other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain neuroregulator site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Incision pain incision site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Lead impedance high</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neuroregulator malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="192"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bloating Abdominal</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="192"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="38" subjects_affected="32" subjects_at_risk="192"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="29" subjects_affected="23" subjects_at_risk="192"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="192"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Heartburn/Dyspepsia</sub_title>
                <counts group_id="E1" events="57" subjects_affected="47" subjects_at_risk="192"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="40" subjects_affected="32" subjects_at_risk="192"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain Abdominal</sub_title>
                <counts group_id="E1" events="38" subjects_affected="32" subjects_at_risk="192"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Emesis (vomiting)</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="192"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Cramps abdominal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="192"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <description>Primarily related to the sensation of therapy.
Generally occurred early with mild to moderate severity.</description>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="192"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Skin reaction to coil/coil adhesion method</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="192"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Energy decreased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="192"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="192"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Reaction to medicines</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="192"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Out of range lab values</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="192"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Vitamin or mineral insufficiency</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="192"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="192"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="192"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="192"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="192"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cold/flu/respiratory tract infection</sub_title>
                <counts group_id="E1" events="170" subjects_affected="93" subjects_at_risk="192"/>
                <counts group_id="E2" events="101" subjects_affected="46" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain neuroregulator site</sub_title>
                <counts group_id="E1" events="47" subjects_affected="42" subjects_at_risk="192"/>
                <counts group_id="E2" events="30" subjects_affected="28" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Wound redness or irritation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="192"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="192"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Incision pain incision site</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="192"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Two confounding efficacy factors: Variable hours of therapy in both arms due to inconsistent external power source use and altered vagal excitability in the control arm due to small electrical inputs delivered to vagal nerves for safety checks.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President of Clinical</name_or_title>
      <organization>EnteroMedics Inc</organization>
      <phone>651-634-3209</phone>
      <email>ktweden@enteromedics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

